The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043Expands Erasca’s ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...
Molecular and clinical characteristics of POLE/POLD1 alterations among patients with colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results